Georgi Stefanov


Georgi Stefanov is the Managing Director of RareDis Solutions, part of Institute for Rare Diseases. He has master’s degrees in medicine (MD), business administration (MBA), PhD in public health, clinical and academic experience. He has passed successfully courses on Innovation, IESE, Spain and Sharpening Strategic Skills, INSEAD, France, while working in multinational healthcare companies – Sanofi, Abbott and Mylan.

Dr. Stefanov is a senior healthcare strategic manager with extensive sales, marketing, medical and market access experience, consistently achieving solid results in challenging and diverse projects across multiple geographies – Europe, Canada, Middle East, CIS and Africa.

He is experienced in framing and driving regional strategies, establishing effective networks between multiple healthcare stakeholders – HCPs, patient’s associations, payers; cross-regional activities – advisory boards, trainings, governance and optimization of processes. Proven commercial track record and P&L responsibility in successfully launching new products, line extensions, developing mature businesses across therapeutic areas, geographies, reimbursement systems and business models. Dr. Stefanov specifically led the pre/launch and reimbursement of Plavix® (clopidogrel), Humira® (adalimumab), Synagis® (palivizumab) for Bulgaria; EMEA East regional strategy and implementation for Influvac® (influenza vaccine), pain, anti-infectives, cardio portfolio; commercial lead in framing Abbott’s global trade channel strategy and cascading it across the region; establishing the foundations, strategy and prelaunch set up for Mylan Oncology/Diabetes biosimilars portfolio for Europe.

As lecturer in City University of Seattle, USA, DLC – Sofia, Georgi Stefanov was teaching Marketing and Marketing research classes in 2006/7. He initiated, led and coordinated the implementation of a Pharmacy partnership project under the auspice of the Pharmaceutical Group of the European Union in 2012, which resulted in framing a Pharmacy guidance for patients with pain. Dr. Stefanov has been a member of the European pharmaceutical working group contributing to the European Commission & European Medicines Agency 2017 project: Biosimilars in the EU / Information guide for HCPs.

Throughout the carrier development, his main approach has been the creation of an environment that drives, motivates and recognizes achievements, coupled with designing and implementing innovative, sustainable “full wrap around” solutions aimed to deliver value and achieve improved patient outcome.